Key findings indicated that, preclinically, the combination treatment resulted in a 42% reduction in the number of intestinal tumors compared to controls, with tumor lysis adverse event rates demonstrating downregulation of AT1R (the pro-tumor axis) and upregulation of ACE2 (the anti-tumor axis), confirming dual RAS modulation. The gene discussed is AGTR1; the disease is neoplasm.